Education
About Us
Working with TipRanks
Follow Us
PYC Therapeutics Limited (AU:PYC)
:PYC
PYC Stock Chart & Stats
AU$1.20
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$1.20
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.85 - AU$1.64
Previous CloseN/A
Volume307.79K
Average Volume (3M)504.73K
Market Cap
AU$854.48M
Enterprise ValueAU$549.20M
Total Cash (Recent Filing)AU$153.05M
Total Debt (Recent Filing)AU$1.02M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Feb 26, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding583,260,440
10 Day Avg. Volume577,664
30 Day Avg. Volume504,725
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)3.84
Price to Sales (P/S)27.69
P/FCF Ratio-12.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.85Price Target Upside137.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.13
Revenue Forecast (FY)AU$13.33M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPYC-003 is now being assessed in a Phase I in healthy volunteers, entering a catalyst-rich period across all of its clinical programs.
Market ValidationNVS Acquisition of RGLS Further Validates MOA for Potentially Best-in-Class PYC-003.
ValuationThe upfront payment of US$7.00 per share infers an EV of US$0.8B – if applied to PYC’s capital structure, this generates a PYC valuation of AU$2.35 per share (US$1.50).
Bears Say
Competition And Market DynamicsAnalyst's recommendation is based on discounted, risk-adjusted multiples of 5 year forecast sales of the company’s three clinical candidates.
Probability Of SuccessApplying a 15% probability to the CVR, increases the valuation to AU$2.70 (US$1.72).
Speculative RiskBloom Burton is initiating research coverage of genetic medicine company, PYC Therapeutics, with a BUY rating (Speculative risk).
PYC Therapeutics Limited News
PYC FAQ
What was PYC Therapeutics Limited’s price range in the past 12 months?
PYC Therapeutics Limited lowest share price was AU$0.85 and its highest was AU$1.64 in the past 12 months.
What is PYC Therapeutics Limited’s market cap?
PYC Therapeutics Limited’s market cap is AU$854.48M.
When is PYC Therapeutics Limited’s upcoming earnings report date?
PYC Therapeutics Limited’s upcoming earnings report date is Feb 26, 2026 which is in 73 days.
How were PYC Therapeutics Limited’s earnings last quarter?
PYC Therapeutics Limited released its earnings results on Aug 28, 2025. The company reported -AU$0.046 earnings per share for the quarter, beating the consensus estimate of -AU$0.079 by AU$0.033.
Is PYC Therapeutics Limited overvalued?
According to Wall Street analysts PYC Therapeutics Limited’s price is currently Undervalued.
Does PYC Therapeutics Limited pay dividends?
PYC Therapeutics Limited does not currently pay dividends.
What is PYC Therapeutics Limited’s EPS estimate?
PYC Therapeutics Limited’s EPS estimate is -0.07.
How many shares outstanding does PYC Therapeutics Limited have?
PYC Therapeutics Limited has 583,260,440 shares outstanding.
What happened to PYC Therapeutics Limited’s price movement after its last earnings report?
PYC Therapeutics Limited reported an EPS of -AU$0.046 in its last earnings report, beating expectations of -AU$0.079. Following the earnings report the stock price went down -0.769%.
Which hedge fund is a major shareholder of PYC Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:PYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PYC Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$2.85 (137.50% Upside)
AU$2.85 (137.50% Upside)
Blogger Sentiment
Bullish
AU:PYC Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.39%
12-Months-Change
Fundamentals
Return on Equity
-40.23%
Trailing 12-Months
Asset Growth
100.88%
Trailing 12-Months
Company Description
PYC Therapeutics Limited
PYC Therapeutics Limited (PYC) is a biotechnology company focused on developing innovative RNA-based therapeutics. The company specializes in next-generation RNA-targeted therapies aimed at treating genetic disorders and diseases, particularly those associated with the central nervous system. PYC leverages its proprietary technology platforms to design and deliver RNA therapeutics that can modify gene expression, offering potential treatments for conditions such as muscle dystrophies and other genetic disorders.
PYC Stock 12 Month Forecast
Average Price Target
AU$2.85
▲(137.50% Upside)
Technical Analysis
Opthea
―
Clinuvel Pharmaceuticals
―
Immutep Ltd
―
Clarity Pharmaceuticals Ltd.
―
Botanix Pharmaceuticals Limited
―
Options Prices
Currently, No data available
---